

# Contrast Nephropathy

Myth or Fact?

Sunil Agrawal, MD, FASN

---

---

---

---

---

---

---

---

## Disclosures

- Speaker for AstraZeneca
- Speaker for Bayer
- Medical Director for DaVita Kidney Care

---

---

---

---

---

---

---

---

## Outline

- CIN vs CA-AKI
- Historic Perspective
- Pathogenesis
- Clinical Presentation and Course
- Risk
- Prevention
- Summary

---

---

---

---

---


---

---

---

## Why talk about Contrast?

- Recent controversy with basic science and clinical studies in conflict → is contrast kidney injury overestimated clinical entity?
- “Renal sim” → selecting out CKD for contrast procedures
  - Do we avoid angiography at the detriment of patients with CKD?
- Has become an integral part of diagnostic testing in modern medicine.




---

---

---

---

---

---

---

---

## CIN vs. CA-AKI???

- Contrast Induced Nephropathy (CIN) VS. Contrast associated AKI (CA-AKI)??
- Often difficult to prove sole injury agent
- Multifactorial
  - Hypotension
  - Intra-aortic balloon pump (IABP)
  - CHF
  - Cholesterol Emboli\*
- Definition of CA-AKI: AKI occurring after administration of iodinated contrast may or may not be directly caused by the contrast material.
- Contrast Nephrotoxic?
  - Based on Animal Studies
  - Large uncontrolled Human trails

---

---

---

---

---

---

---

---

## Historic Perspective

- First report of contrast media related Acute Kidney Injury (AKI) was - 1954
  - Multiple Myeloma patient developed anuria following intravenous pyelography
- In 1980s larger case series began to appear
  - Contrast media exposure from coronary angiography
  - Particularly patients with CKD and DM




---

---

---

---

---

---

---

---

## The Controversy of Existence: The Evidence???

- Most conclusion of nephrotoxicity have been from prospective randomized trials (RCT)
- Previous assertions and contradictions are due:
  - Limitations non-randomized trials, uncontrolled, and observational
- RCT(S) risk of AKI:
  - high-osmolar contrast media >>> low-osmolar contrast media
- RCT(s) show prevention of contrast associated AKI:
  - Volume expansion prophylaxis
- Difference in risk in Arterial versus Venous contrast media:
  - Comorbidities of patient
  - Procedural Risk
  - Contrast Volumes
    - Similar rate when comparable amounts used
    - Grams of iodine contrast per ml/min of eGFR

---

---

---

---

---



---

---

---

## Pathogenesis of Injury

- Suspected from Animal Models:
  - Vasoconstriction
  - Medullary Toxicity
  - Direct Cytotoxic effects




---

---

---

---


---

---

---

---

## Pathogenesis of Injury




---

---

---

---

---


---

---

---

### Clinical Presentation and Course

- Acute Kidney Injury typically has rapid recovery.
- Suspected AKI more “multihit” for development of ATN
- Rise in creatinine typically occur in 24 to 48 hours after exposure
- Typically mild rise in creatinine nonoliguric
- \*Oliguria and Severe AKI are less common findings of CIN




---

---

---

---

---

---

---

---

### Staging of AKI

#### AKI Staging – KDIGO

AKI stage	Serum Creatinine criteria	Urine output criteria
1	SCr increase $\geq 26 \mu\text{mol/L}$ within 48 hrs or SCr increase $\geq 1.5$ -2 fold from baseline	$<0.5 \text{ mL/kg/hr}$ for 6 consecutive hrs
2	SCr increase $\geq 2$ -3 fold from baseline	$<0.5 \text{ mL/kg/hr}$ for 12 hrs
3	SCr increase $\geq 3$ fold from baseline or SCr increase $\geq 54 \mu\text{mol/L}$ or initiated on RRT (irrespective of stage at time of initiation)	$<0.3 \text{ mL/kg/hr}$ for 24 hr or anuria for 12 hr

---

---

---

---

---


---

---

---

### Clinical Presentation and Course

- Early presentation may be a “Pre-Renal” Picture:
  - Vasoconstriction → “Sodium Avid State”
  - FENA  $< 1\%$
- Later phase maybe Acute tubular necrosis/tubular injury
- Renal US would be normal
- Typically Bland UA
  - Doesn't exclude if present
- Kidney Bx non-specific ATN




---

---

---

---

---

---

---

---

### Clinical Presentation and Course

- Most patients kidney function improves 3 to 7 days
- Dialysis is rare for CIN
  - Multiple hit
  - DM/CKD
- Persistent CKD?
  - Usually recovery to baseline
  - DM/CKD at risk for continued chronic elevation (CKD or worsening CKD)



---

---

---

---

---

---

---

### Risk for Contrast Associated and Induced Nephropathy

- |  |  |
|--|--|
| <b>Procedure Related</b>   | <b>Patient Related</b>   |
| <ul style="list-style-type: none"><li>• Volume of Contrast</li><li>• Multiple exposures</li><li>• High-osmolar contrast</li><li>• Intra-arterial??</li></ul> | <ul style="list-style-type: none"><li>• <u>Chronic Kidney Disease**</u></li><li>• <u>DM**</u></li><li>• <u>Volume depletion</u></li><li>• <u>Reduced cardiac output</u></li><li>• <u>Concomitant nephrotoxins</u></li><li>• <u>Proteinuria**</u><ul style="list-style-type: none"><li>• &gt;300 mg/day of albuminuria</li><li>• &gt;500 mg/day of proteinuria</li></ul></li><li>• <u>Age**</u></li></ul> |

---

---

---

---

---

---

---

### Risk for Contrast Associated and Induced Nephropathy

- eGFR > 60 mL/min/1.73 m2 negligible risk
- eGFR >30 to 44 mL/min/1.73 m2 negligible risk???
- eGFR between 30 and 44 mL/min/1.73m2 are at intermediate risk
- eGFR < 30 mL/min/1.73m2 are greatest at risk
- Diabetes increases risk in all patients

---

---

---

---

---

---

---

## Risk for Contrast Associated and Induced Nephropathy

- Question: "Is it okay to give contrast to patient with abnormal kidney function?"
- COMPLEX ANSWER:
  - Must always weigh risk versus benefit
  - Emergency versus elective
  - "Will this change my management?"
  - Stability of Creatinine
  - Alternative Studies?

---

---

---

---

---

---

---

---

## Potential Differential Diagnosis

- Cholesterol Emboli (intra-arterial)
  - Livedo reticularis
  - Urine eosinophils
  - Hypocomplementemia
- Pre-renal Injury (ie Heart Failure)
  - Venous Congestion
  - Decreased Stroke Volume



---

---

---

---

---

---

---

---

## Prevention

- Use minimal volume of contrast
  - Staged Procedures
  - Wait at least 72 hours for next contrast media load
  - Carbon dioxide below the diaphragm
  - Use low-osmolal (Grade 1B) or iso-osmolal agents
- Isotonic Fluids
- (Grade 1B, assuming no contraindication)
  - No difference between Bicarbonate or Normal Saline (Grade 1B)
  - Outpatient: 3 mL/kg over one hour pre and 1-1.5 mL/mg/kg/hr for 4 to 6 hours post
  - Inpatients: 1 mL/kg/hr for 6 to 12 hours pre and post
- Dialysis
  - Hasn't been shown to have any clear benefit in prevention

---

---

---

---


---

---

---


---

## Prevention



Bicarbonate vs. Normal Saline  
CJASN October 2009


## Prevention



## Prevention

- **Statins**
  - Some studies suggested risk reduction
  - Not recommended as standard prevention strategy
- **Diuretics or mannitol**
  - Not recommended
- **NAC (Acetylcysteine)**
  - Meta-analyses yielded conflicting results
  - Not recommended as standard (grade 2B)

## Prevention



The efficacy of NAC

---

---

---

---

---

---

---

---

---

---

---

---

## Types of Contrast

Commonly used iodinated contrast agents

Name	Type	Iodine Content	Osmolality		
Ionic	Diatrizoate (Hypaque 50)	Ionic Monomer	360	1650	High Osmolar
	Iopamide	Ionic	370	2100	
	Iopaque Contrast 270	Ionic	320	880	
Non-Ionic	Iopamidate (Hexabrix)	Ionic	320	880	Low Osmolar
	Iopasol (Istosol 270)	Non-ionic monomer	370	796	
	Iohexol (Omnipaque 350)	Non-ionic	350	884	
Non-Ionic	Iodinated	Non-ionic dimer	320	290	Iso Osmolar
	Visipaque 320	Non-ionic dimer	320	290	

---

---

---

---

---

---

---

---

---

---

---

---

## Gadolinium/MRI contrast media

- Not nephrotoxic
- Can Cause nephrogenic systemic fibrosis (NSF) → typically fatal
- Would Avoid use of Group I and Group III agents in eGFR < 30 ml/min/1.73 m<sup>2</sup>
- Consider alternative study or no contrast (gadolinium) if eGFR < 30 ml/min/1.73m<sup>3</sup>
- If no choice, use Group II agent
  - Few if any reported cases of NSF
- Patients on dialysis do require post administration dialysis with gadolinium. (unclear if this is protective)

---

---

---

---

---

---

---

---

---

---

---

---



## Types of Gadolinium

### 2016 ACR Manual, Version 10.2

#### GBCAs Are Divided Into 3 Risk Categories

##### Group 1

Agents associated with the greatest number of NSF cases (gadotamide [OrniScan<sup>®</sup>], gadopentate [Magnevist<sup>®</sup>], and gadoversetamide [Dotarem<sup>®</sup>])

##### Group 2

Agents associated with few, if any, unconfounded cases of NSF (gadobenate [Multihance<sup>®</sup>], gadoteridol [ProHance<sup>®</sup>], gadoterate [Dotarem<sup>®</sup>], and gadobutrol [Gadovist<sup>®</sup>])

##### Group 3

Agents that have only recently appeared on the market in the United States (ie, unknown risk) (gadofosveset [Ablavar<sup>®</sup>] and gadovate [Eovist<sup>®</sup>])

ACR website

---

---

---

---

---

---

---

---

## Summary

- Contrast injury to the kidney does exist:
  - CIN
  - CA-AKI
- Isotonic fluids are a good strategy for prevention
- Weigh the benefits versus the risks
- Consider alternative testing if advanced CKD
- Diabetes matters!



The Proud Purple Podocyte

---

---

---

---

---

---

---

---